Save your place

Sign in to WhoBought

Please try again later.

Entrada Therapeutics, Inc. (TRDA) institutional ownership

Market cap$220M SectorHealthcare
Funds holding · Q1 2026
107
reported TRDA position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
62 buyers · 45 sellers

Entrada Therapeutics, Inc. (TRDA) price and institutional activity

Dates

Q1 2026

$0 bought by 62 investors
Jones Hill Capital LPBlackRock +60 more
$0 sold by 45 investors
Algert Global LLCRoyce & Associates LP +43 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

Entrada Therapeutics, Inc. (TRDA) institutional activity · 107

Investor Type Est. change Change Δ Own Date
Jones Hill Capital LP · New
Change +374K Date Q1 2026
Jones Hill Capital LP New· Q1 2026 +374K Q1 2026
BlackRock · Added
Change +212K Date Q1 2026
BlackRock Added· Q1 2026 +212K Q1 2026
Longaeva Partners L.P. · New
Change +205K Date Q1 2026
Longaeva Partners L.P. New· Q1 2026 +205K Q1 2026
Tcg Crossover Management, LLC · Added
Change +199K Date Q1 2026
Tcg Crossover Management, LLC Added· Q1 2026 +199K Q1 2026
T. Rowe Price Associates · Added
Change +199K Date Q1 2026
T. Rowe Price Associates Added· Q1 2026 +199K Q1 2026
Lynx1 Capital Management LP · Added
Change +160K Date Q1 2026
Lynx1 Capital Management LP Added· Q1 2026 +160K Q1 2026
Nantahala Capital Management, LLC · New
Change +159K Date Q1 2026
Nantahala Capital Management, LLC New· Q1 2026 +159K Q1 2026
Algert Global LLC · Exited
Change −129K Δ Own −100.0% Date Q1 2026
Algert Global LLC Exited· Q1 2026 −129K −100.0% Q1 2026
Royce & Associates LP · Reduced
Change −126K Date Q1 2026
Royce & Associates LP Reduced· Q1 2026 −126K Q1 2026
Nuveen, LLC · Added
Change +119K Date Q1 2026
Nuveen, LLC Added· Q1 2026 +119K Q1 2026
Sphera Funds Management Ltd. · Exited
Change −111K Δ Own −100.0% Date Q1 2026
Sphera Funds Management Ltd. Exited· Q1 2026 −111K −100.0% Q1 2026
Acuta Capital Partners, LLC · New
Change +89K Date Q1 2026
Acuta Capital Partners, LLC New· Q1 2026 +89K Q1 2026
Qube Research & Technologies Ltd · Reduced
Change −89K Date Q1 2026
Qube Research & Technologies Ltd Reduced· Q1 2026 −89K Q1 2026
Morgan Stanley · Reduced
Change −84K Date Q1 2026
Morgan Stanley Reduced· Q1 2026 −84K Q1 2026
Citadel Advisors LLC Reduced· Q1 2026 −78K −26.6% Q1 2026
Data through Q1 2026 · filed Jun 2, 2026
15 of 107

Famous investor activity in Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics, Inc. (TRDA) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Parmar Kush · Director Grant (A) 19K
Owned 19K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Parmar Kush Director Grant (A) 19K 19K Jun 10, 2026 Jun 12, 2026
Kim Peter S. · Director Grant (A) 19K
Owned 19K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Kim Peter S. Director Grant (A) 19K 19K Jun 10, 2026 Jun 12, 2026
Chapman Gina · Director Grant (A) 19K
Owned 19K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Chapman Gina Director Grant (A) 19K 19K Jun 10, 2026 Jun 12, 2026
Radhakrishnan Maha · Director Grant (A) 19K
Owned 19K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Radhakrishnan Maha Director Grant (A) 19K 19K Jun 10, 2026 Jun 12, 2026
Thistle Mary · Director Grant (A) 19K
Owned 19K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Thistle Mary Director Grant (A) 19K 19K Jun 10, 2026 Jun 12, 2026
Zeiher Bernhardt G. · Director Grant (A) 19K
Owned 19K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Zeiher Bernhardt G. Director Grant (A) 19K 19K Jun 10, 2026 Jun 12, 2026
Zeiher Bernhardt G. · Director Buy +$29K
Price $5.86 Qty +5K Owned 5K Trade date May 20, 2026 Filed date May 21, 2026
Zeiher Bernhardt G. Director Buy $5.86 +5K +$29K 5K May 20, 2026 May 21, 2026
Sethuraman Natarajan · Officer Sell −$399K
Price $15.39 Qty −26K Owned 216K Trade date May 4, 2026 Filed date May 4, 2026
Sethuraman Natarajan Officer Sell $15.39 −26K −$399K 216K May 4, 2026 May 4, 2026
Dowden Nathan J. · Officer Sell −$230K
Price $15.33 Qty −15K Owned 199K Trade date May 4, 2026 Filed date May 4, 2026
Dowden Nathan J. Officer Sell $15.33 −15K −$230K 199K May 4, 2026 May 4, 2026
Dowden Nathan J. · Officer 2 operations 0
Price $1.74 Owned 50K Trade date May 4, 2026 Filed date May 4, 2026
Dowden Nathan J. Officer 2 operations $1.74 0 50K May 4, 2026 May 4, 2026
Wentworth Kory James · CFO Sell −$32K
Price $12.95 Qty −2K Owned 119K Trade date Apr 1, 2026 Filed date Apr 2, 2026
Wentworth Kory James CFO Sell $12.95 −2K −$32K 119K Apr 1, 2026 Apr 2, 2026
Dowden Nathan J. · Officer Sell −$155K
Price $13.05 Qty −12K Owned 199K Trade date Mar 10, 2026 Filed date Mar 11, 2026
Dowden Nathan J. Officer Sell $13.05 −12K −$155K 199K Mar 10, 2026 Mar 11, 2026
Wentworth Kory James · Officer Sell −$148K
Price $13.02 Qty −11K Owned 122K Trade date Mar 10, 2026 Filed date Mar 11, 2026
Wentworth Kory James Officer Sell $13.02 −11K −$148K 122K Mar 10, 2026 Mar 11, 2026
Dowden Nathan J. · Officer Sell −$41K
Price $13.02 Qty −3K Owned 210K Trade date Mar 9, 2026 Filed date Mar 11, 2026
Dowden Nathan J. Officer Sell $13.02 −3K −$41K 210K Mar 9, 2026 Mar 11, 2026
Wentworth Kory James · Officer Sell −$66K
Price $13.00 Qty −5K Owned 133K Trade date Mar 9, 2026 Filed date Mar 11, 2026
Wentworth Kory James Officer Sell $13.00 −5K −$66K 133K Mar 9, 2026 Mar 11, 2026
15 of 39
15 of 39 Sign in to continue to older insider transactions.

Entrada Therapeutics, Inc. (TRDA) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Baker Bros. Advisors LP 4.9M
% of shares outstanding 13.2% Filing date Jun 26, 2024
Baker Bros. Advisors LP 4.9M 13.2% Jun 26, 2024
T. Rowe Price Associates 3.0M
% of shares outstanding 8.2% Filing date Nov 14, 2024
T. Rowe Price Associates 3.0M 8.2% Nov 14, 2024
Roche Finance Ltd 2.6M
% of shares outstanding 6.9% Filing date Feb 14, 2025
Roche Finance Ltd 2.6M 6.9% Feb 14, 2025
3 of 3

Entrada Therapeutics, Inc. (TRDA) ownership FAQ

Who owns TRDA?

107 reporting institutions disclosed TRDA position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.